Physician profile
Christopher Bell
NPI 1982193660
$4,478.16
in general payments reported to CMS, 2019-2025
24 companies · $994 in 2025
The $994 reported for 2025 was more than what 85% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $42.36 · 2022: $235 · 2023: $261 · 2024: $2,945 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624 · Travel and Lodging: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,624.01 |
| Travel and Lodging | $1,576.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $2,406.67 | 2024-2025 | Atriclip Laa Exclusion System |
| Merck Sharp & Dohme LLC | $294.17 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $282.58 | 2025 | S-Icd System Magnet, General - Therapies, Cds - Mct/Cem Monitoring |
| Biosense Webster, INC. | $242.64 | 2024-2025 | Carto 3, Na |
| Novartis Pharmaceuticals Corporation | $236.82 | 2021-2025 | |
| Pfizer INC. | $162.14 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $144.07 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $124.91 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.32 | 2022-2025 | Jardiance |
| Medtronic, INC. | $82.02 | 2024-2025 | Linq II |
| Janssen Pharmaceuticals, INC | $55.41 | 2022-2024 | Xarelto |
| Cvrx, INC. | $44.00 | 2025 | Barostim Neo System |
| Impulse Dynamics (USA) INC. | $40.03 | 2025 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $32.75 | 2024 | Brilinta |
| Irhythm Technologies, INC. | $27.65 | 2024 | Zio Xt Patch, Zio Monitor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $24.71 | 2024 | Arcalyst |
| Abbott Laboratories | $24.32 | 2025 | Navitor |
| Abiomed | $24.30 | 2025 | |
| Alnylam Pharmaceuticals INC. | $24.25 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $23.33 | 2023 | Arcalyst |
| Bayer Healthcare Pharmaceuticals INC. | $22.95 | 2023 | |
| Novo Nordisk INC | $20.33 | 2025 | Wegovy |
| Edwards Lifesciences Corporation | $19.09 | 2025 | Sapien 3 Ultra Resilia |
| Scpharmaceuticals INC. | $13.70 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Bell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.